This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The small molecule CMO/CDMO market size has grown strongly in recent years. It will grow from $50.58 billion in 2024 to $54.58 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to favorable government support, cost-effective solutions, growing complexity in drug development, industry consolidation, focus on core competencies.
The small molecule CMO/CDMO market size is expected to see strong growth in the next few years. It will grow to $73.3 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rise in drug pipelines, globalization of pharmaceutical operations, demand for flexible manufacturing, regulatory compliance expertise, biopharmaceutical convergence. Major trends in the forecast period include sustainable and green manufacturing practices, increased collaboration and partnerships, personalized medicine and niche therapies, rise in virtual and virtual-to-reality companies, integration of digital technologies, rapid response manufacturing.
The increasing demand for pharmaceuticals is anticipated to drive the growth of the small-molecule CMO/CDMO market in the future. The pharmaceutical industry encompasses the discovery, development, and production of drugs and medicines by both government and private sectors. Small-molecule CMO/CDMO services are utilized in the pharmaceutical industry to outsource various functions, such as the development, manufacturing, and packaging of small-molecule drugs. This outsourcing enables pharmaceutical companies to reduce costs, save time, and streamline their processes. For example, in August 2024, the Government of Canada, a national government agency, reported that domestic exports in the pharmaceutical sector rose to $9.59 billion USD (12.79 billion CAD) in 2022, an increase from 10.71 billion CAD in 2021. Additionally, imports rose to 30.21 billion CAD, up from 26.63 billion CAD in 2021. Thus, the growing demand for pharmaceuticals is a key factor driving the expansion of the small-molecule CMO/CDMO market.
Major companies in the small-molecule CMO/CDMO market are focusing on innovative technologies to enhance CDMO services, such as the state-of-the-art small-molecule platform in Shanghai. This platform represents cutting-edge technological innovations aimed at developing and producing small-molecule drugs more efficiently. In June 2023, Porton Pharma Solutions Ltd., a China-based pharmaceutical company, launched a state-of-the-art small-molecule platform in Shanghai. This platform adopts a holistic approach by combining advanced technologies and methodologies to advance the entire lifecycle of small-molecule pharmaceuticals. It offers one-stop-shop solutions, flexibility, availability, and digital transformation.
In March 2023, Catalent Inc., a US-based pharmaceutical company, entered into a partnership with Grünentha GmbH, a Germany-based pharmaceutical company. This partnership is focused on expediting clinical development timelines for an orally dosed small molecule in Grünenthal's pipeline. The collaboration aims to improve the bioavailability of the small molecule and reduce the Phase 1 development timeline. Grünenthal GmbH is actively engaged in partnerships and agreements with contract development and manufacturing organizations (CDMOs).
Major companies operating in the small molecule CMO/CDMO market report are Patheon NV (Thermo Fisher Scientific), GlaxoSmithKline, Johnson Matthey PLC, Lonza Group Ltd., WuXi AppTec, Catalent Inc., Aurobindo Pharma, Fareva, Aesica Pharmaceuticals Limited, Siegfried holdings AG, Recipharm AB, Jubilant Life Sciences Limited, Almac Group, Piramal Pharma Solutions, Oxford Chemicals Inc., Syngene International Limited, Novasep, Pfizer CentreOne, GVK Biosciences, ChemPartner, Avid Bioservices Inc., Dishman Carbogen Amcis Ltd., ProChem Inc., Metrics Contract Services.
North America was the largest region in the Small Molecule CMO/CDMO market in 2024. The regions covered in the Small Molecule CMO/CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the Small Molecule CMO/CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market consists of revenues earned by entities by providing services such as drug development services, process scale-up, quality control and testing, technology transfer, and clinical trial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market also includes sales of active pharmaceutical ingredients, drug intermediates, and drug formulation. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
A small-molecule Contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) is a business entity that offers services to pharmaceutical companies on a contractual basis. These services encompass various aspects of the pharmaceutical development lifecycle, including contract development, manufacturing, and packaging of small-molecule drugs. Small-molecule CMOs/CDMOs play a crucial role in assisting other companies in the pharmaceutical industry to complete projects and navigate through the regulatory submission process.
Small-molecule Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) are primarily classified into two categories, small-molecule drug products and small-molecule Active Pharmaceutical Ingredient (API). The term "small-molecule drug product" denotes the final form of a medicinal product that incorporates an active pharmaceutical ingredient composed of small molecules. This involves comprehensive stages, including clinical, commercial, and preclinical development. These drug products find applications in therapeutic areas such as oncology, neurology, infectious diseases, cardiovascular diseases, respiratory disorders, metabolic disorders, among others. The end-users of these services are entities specializing in cardiovascular, oncology, diabetes, and immunological disorders.
The small-molecule CMO/CDMO market research report is one of a series of new reports that provides small-molecule CMO/CDMO market statistics, including small-molecule CMO/CDMO industry global market size, regional shares, competitors with a small-molecule CMO/CDMO market share, detailed small-molecule CMO/CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the small-molecule CMO/CDMO industry. This small-molecule CMO/CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The small molecule CMO/CDMO market size has grown strongly in recent years. It will grow from $50.58 billion in 2024 to $54.58 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to favorable government support, cost-effective solutions, growing complexity in drug development, industry consolidation, focus on core competencies.
The small molecule CMO/CDMO market size is expected to see strong growth in the next few years. It will grow to $73.3 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rise in drug pipelines, globalization of pharmaceutical operations, demand for flexible manufacturing, regulatory compliance expertise, biopharmaceutical convergence. Major trends in the forecast period include sustainable and green manufacturing practices, increased collaboration and partnerships, personalized medicine and niche therapies, rise in virtual and virtual-to-reality companies, integration of digital technologies, rapid response manufacturing.
The increasing demand for pharmaceuticals is anticipated to drive the growth of the small-molecule CMO/CDMO market in the future. The pharmaceutical industry encompasses the discovery, development, and production of drugs and medicines by both government and private sectors. Small-molecule CMO/CDMO services are utilized in the pharmaceutical industry to outsource various functions, such as the development, manufacturing, and packaging of small-molecule drugs. This outsourcing enables pharmaceutical companies to reduce costs, save time, and streamline their processes. For example, in August 2024, the Government of Canada, a national government agency, reported that domestic exports in the pharmaceutical sector rose to $9.59 billion USD (12.79 billion CAD) in 2022, an increase from 10.71 billion CAD in 2021. Additionally, imports rose to 30.21 billion CAD, up from 26.63 billion CAD in 2021. Thus, the growing demand for pharmaceuticals is a key factor driving the expansion of the small-molecule CMO/CDMO market.
Major companies in the small-molecule CMO/CDMO market are focusing on innovative technologies to enhance CDMO services, such as the state-of-the-art small-molecule platform in Shanghai. This platform represents cutting-edge technological innovations aimed at developing and producing small-molecule drugs more efficiently. In June 2023, Porton Pharma Solutions Ltd., a China-based pharmaceutical company, launched a state-of-the-art small-molecule platform in Shanghai. This platform adopts a holistic approach by combining advanced technologies and methodologies to advance the entire lifecycle of small-molecule pharmaceuticals. It offers one-stop-shop solutions, flexibility, availability, and digital transformation.
In March 2023, Catalent Inc., a US-based pharmaceutical company, entered into a partnership with Grünentha GmbH, a Germany-based pharmaceutical company. This partnership is focused on expediting clinical development timelines for an orally dosed small molecule in Grünenthal's pipeline. The collaboration aims to improve the bioavailability of the small molecule and reduce the Phase 1 development timeline. Grünenthal GmbH is actively engaged in partnerships and agreements with contract development and manufacturing organizations (CDMOs).
Major companies operating in the small molecule CMO/CDMO market report are Patheon NV (Thermo Fisher Scientific), GlaxoSmithKline, Johnson Matthey PLC, Lonza Group Ltd., WuXi AppTec, Catalent Inc., Aurobindo Pharma, Fareva, Aesica Pharmaceuticals Limited, Siegfried holdings AG, Recipharm AB, Jubilant Life Sciences Limited, Almac Group, Piramal Pharma Solutions, Oxford Chemicals Inc., Syngene International Limited, Novasep, Pfizer CentreOne, GVK Biosciences, ChemPartner, Avid Bioservices Inc., Dishman Carbogen Amcis Ltd., ProChem Inc., Metrics Contract Services.
North America was the largest region in the Small Molecule CMO/CDMO market in 2024. The regions covered in the Small Molecule CMO/CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the Small Molecule CMO/CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market consists of revenues earned by entities by providing services such as drug development services, process scale-up, quality control and testing, technology transfer, and clinical trial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market also includes sales of active pharmaceutical ingredients, drug intermediates, and drug formulation. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
A small-molecule Contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) is a business entity that offers services to pharmaceutical companies on a contractual basis. These services encompass various aspects of the pharmaceutical development lifecycle, including contract development, manufacturing, and packaging of small-molecule drugs. Small-molecule CMOs/CDMOs play a crucial role in assisting other companies in the pharmaceutical industry to complete projects and navigate through the regulatory submission process.
Small-molecule Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) are primarily classified into two categories, small-molecule drug products and small-molecule Active Pharmaceutical Ingredient (API). The term "small-molecule drug product" denotes the final form of a medicinal product that incorporates an active pharmaceutical ingredient composed of small molecules. This involves comprehensive stages, including clinical, commercial, and preclinical development. These drug products find applications in therapeutic areas such as oncology, neurology, infectious diseases, cardiovascular diseases, respiratory disorders, metabolic disorders, among others. The end-users of these services are entities specializing in cardiovascular, oncology, diabetes, and immunological disorders.
The small-molecule CMO/CDMO market research report is one of a series of new reports that provides small-molecule CMO/CDMO market statistics, including small-molecule CMO/CDMO industry global market size, regional shares, competitors with a small-molecule CMO/CDMO market share, detailed small-molecule CMO/CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the small-molecule CMO/CDMO industry. This small-molecule CMO/CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Small Molecule CMO/CDMO Market Characteristics3. Small Molecule CMO/CDMO Market Trends and Strategies4. Small Molecule CMO/CDMO Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global Small Molecule CMO/CDMO Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Small Molecule CMO/CDMO Market34. Recent Developments in the Small Molecule CMO/CDMO Market
5. Global Small Molecule CMO/CDMO Growth Analysis and Strategic Analysis Framework
6. Small Molecule CMO/CDMO Market Segmentation
7. Small Molecule CMO/CDMO Market Regional and Country Analysis
8. Asia-Pacific Small Molecule CMO/CDMO Market
9. China Small Molecule CMO/CDMO Market
10. India Small Molecule CMO/CDMO Market
11. Japan Small Molecule CMO/CDMO Market
12. Australia Small Molecule CMO/CDMO Market
13. Indonesia Small Molecule CMO/CDMO Market
14. South Korea Small Molecule CMO/CDMO Market
15. Western Europe Small Molecule CMO/CDMO Market
16. UK Small Molecule CMO/CDMO Market
17. Germany Small Molecule CMO/CDMO Market
18. France Small Molecule CMO/CDMO Market
19. Italy Small Molecule CMO/CDMO Market
20. Spain Small Molecule CMO/CDMO Market
21. Eastern Europe Small Molecule CMO/CDMO Market
22. Russia Small Molecule CMO/CDMO Market
23. North America Small Molecule CMO/CDMO Market
24. USA Small Molecule CMO/CDMO Market
25. Canada Small Molecule CMO/CDMO Market
26. South America Small Molecule CMO/CDMO Market
27. Brazil Small Molecule CMO/CDMO Market
28. Middle East Small Molecule CMO/CDMO Market
29. Africa Small Molecule CMO/CDMO Market
30. Small Molecule CMO/CDMO Market Competitive Landscape and Company Profiles
31. Small Molecule CMO/CDMO Market Other Major and Innovative Companies
35. Small Molecule CMO/CDMO Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Small Molecule CMO/CDMO Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on small molecule cmo/cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for small molecule cmo/cdmo? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The small molecule cmo/cdmo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Small Molecule Drug Product; Small Molecule API2) By Stage Type: Clinical; Commercial; Preclinical
3) By Therapeutic Area: Oncology; Neurology; Infectious Disease; Cardiovascular Disease; Respiratory Disorders; Metabolic Disorders; Other Therapeutics
4) By Application: Cardiovascular; Oncology; Diabetes; Immunological Disorders
Subsegments:
1) By Small Molecule Drug Product: Solid Dosage Forms (Tablets, Capsules); Liquid Dosage Forms (Injectables, Solutions); Topical Dosage Forms2) By Small Molecule API (Active Pharmaceutical Ingredient): Generic APIs; Branded APIs; Custom Synthesis APIs
Key Companies Mentioned: Patheon NV (Thermo Fisher Scientific); GlaxoSmithKline; Johnson Matthey plc; Lonza Group Ltd.; WuXi AppTec
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Small Molecule CMO/CDMO market report include:- Patheon NV (Thermo Fisher Scientific)
- GlaxoSmithKline
- Johnson Matthey plc
- Lonza Group Ltd.
- WuXi AppTec
- Catalent Inc.
- Aurobindo Pharma
- Fareva
- Aesica Pharmaceuticals Limited
- Siegfried holdings AG
- Recipharm AB
- Jubilant Life Sciences Limited
- Almac Group
- Piramal Pharma Solutions
- Oxford Chemicals Inc.
- Syngene International Limited
- Novasep
- Pfizer CentreOne
- GVK Biosciences
- ChemPartner
- Avid Bioservices Inc.
- Dishman Carbogen Amcis Ltd
- ProChem Inc.
- Metrics Contract Services
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 54.58 Billion |
| Forecasted Market Value ( USD | $ 73.3 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
